A disintegrin and metalloprotease 12 (ADAM12) is a prognostic factor in resected pathological stage I lung adenocarcinoma

Journal of Surgical Oncology

Volumn 100, Issue 3, 2009, Pages 267-272

  Mino, Nobuya ^a   Miyahara, Ryo ^a   Nakayama, Ei ^a   Takahashi, Tsuyoshi ^a   Takahashi, Ayuko ^a   Iwakiri, Shotaro ^a   Sonobe, Makoto ^a   Okubo, Kenichi ^a   Hirata, Toshiki ^a   Sehara, Atsuko ^b   Date, Hiroshi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

ADAM12; Lung cancer; Prognosis; Surgery

Indexed keywords

A DISTEGRIN AND METALLOPROTEASE 12; ADAM PROTEIN; UNCLASSIFIED DRUG; ADAM 12 PROTEIN; DISINTEGRIN; MEMBRANE PROTEIN; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOCARCINOMA; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; RETROSPECTIVE STUDY; TUMOR CELL LINE; TUMOR RECURRENCE;

ADAM PROTEINS; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; DISINTEGRINS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 70249102466     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21313     Document Type: Article

References (40)

1. Bryant A, Cerfolio RJ: Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest 2007;132:185-192. (Pubitemid 47068220)
2. Alberg AJ, Samet JM: Epidemiology of lung cancer. Chest 2003;123:21S-49S.
3. Devesa SS, Bray F, Vizcaino AP, et al.: International lung cancer trends by histologic type: Male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005;117:294-299. (Pubitemid 41379403)
4. Arribas J, Bech-Serra JJ, Santiago-Josefat B: ADAMs, cell migration and cancer. Cancer Metastasis Rev 2006;25:57-68.
5. Mochizuki S, Okada Y: ADAMs in cancer cell proliferation and progression. Cancer Sci 2007;98:621-628. (Pubitemid 46563436)
6. Seals DF, Courtneidge SA: The ADAMs family of metalloproteases: Multidomain proteins with multiple functions. Genes Dev 2003;17:7-30.
7. Yagami-Hiromasa T, Sato T, Kurisaki T, et al.: A metalloprotease- disintegrin participating in myoblast fusion. Nature 1995;377:652-656.
8. Gilpin BJ, Loechel F, Mattei MG, et al.: A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. J Biol Chem 1998;273:157-166. (Pubitemid 28042189)
9. Kveiborg M, Albrechtsen R, Couchman JR, et al.: Cellular roles of ADAM12 in health and disease. Int J Biochem Cell Biol 2008;40:1685-1702.
10. Iba K, Albrechtsen R, Gilpin BJ, et al.: Cysteine-rich domain of human ADAM 12 (meltrin alpha) supports tumor cell adhesion. Am J Pathol 1999;154:1489-1501. (Pubitemid 29226444)
11. Kveiborg M, Fröhlich C, Albrechtsen R, et al.: A role for ADAM12 in breast tumor progression and stromal cell apoptosis. Cancer Res 2005;65:4754-4761. (Pubitemid 40740812)
12. Lendeckel U, Kohl J, Arndt M, et al.: Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol 2005;131:41-48. (Pubitemid 40064456)
13. Frohlich C, Albrechtsen R, Dyrskjot L, et al.: Molecular profiling of ADAM12 in human bladder cancer. Clin Cancer Res 2006;12:7359-7368. (Pubitemid 46095409)
14. Le Pabic H, Bonnier D, Wewer UM, et al.: ADAM12 in human liver cancers: TGFbeta-regulated expression in stellate cells is associated with matrix remodeling. Hepatology 2003;37:1056-1066. (Pubitemid 36538682)
15. Rocks N, Paulissen G, Quesada Calvo F, et al.: Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human nonsmall-cell lung carcinomas (NSCLC). Br J Cancer 2006;94:724-730. (Pubitemid 43361905)
16. Kodama T, Ikeda E, Okada A, et al.: ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am J Pathol 2004;165:1743-1753. (Pubitemid 39435171)
17. Wu E, Croucher PI, McKie N: Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies. Biochem Biophys Res Commun 1997;235:437-442. (Pubitemid 27313727)
18. Tian BL, Wen JM, Zhang M, et al.: The expression of ADAM12 (meltrin a) in human giant cell tumours of bone. Mol Pathol 2002;55:394-397. (Pubitemid 35454515)
19. Mountain CF: Revision in the international system for staging lung cancer. Chest 1997;111:1710-1717. (Pubitemid 27260107)
20. Travis WD, Colby TV, Corrin B, et al.: Histological typing of lung and pleural tumors. In: Travis WD, editor. World Health Organization International Histological Classification of tumors. Histological typing of lung and pleural tumors, 3rd edition. Berlin: Springer; 1999. pp. 21-66.
21. Asakura M, Kitakaze M, Takashima S, et al.: Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy. Nat Med 2002;8:35-40. (Pubitemid 34101726)
22. Kurisaki T, Masuda A, Sudo K, et al.: Phenotypic analysis of Meltrin alpha (ADAM12)-deficient mice: Involvement of Meltrin alpha in adipogenesis and myogenesis. Mol Cell Biol 2003;23:55-61. (Pubitemid 36008500)
23. Horiuchi K, Zhou HM, Kelly K, et al.: Evaluation of the contributions of ADAMs9, 12, 15 17 and 19 to heart development and ectodomain shedding of neuregulins beta1 and beta2. Dev Biol 2005;283:459-471.
24. Dyczynska E, Sun D, Yi H, et al.: Proteolytic processing of deltalike 1 by ADAM proteases. J Biol Chem 2007;282:436-444. (Pubitemid 47076599)
25. Atfi A, Dumont E, Colland F, et al.: The disintegrin and metalloproteinase ADAM12 contributes to TGF-beta signaling through interaction with the type II receptor. J Cell Biol 2007;178:201-208. (Pubitemid 47076457)
26. Thodeti CK, Albrechtsen R, Grauslund M, et al.: ADAM12/syndecan-4 signaling promotes beta 1 integrin-dependent cell spreading through protein kinase C alpha and RhoA. J Biol Chem 2003;278:9576-9584. (Pubitemid 36800452)
27. Huang J, Bridges LC, White JM: Selective modulation of integrin-mediated cell migration by distinct ADAM family members. Mol Biol Cell 2005;16:4982-4991. (Pubitemid 41416475)
28. Kawaguchi N, Sundberg C, Kveiborg M, et al.: ADAM12 induces actin cytoskeleton and extracellular matrix reorganization during early adipocyte differentiation by regulating beta1 integrin function. J Cell Sci 2003;116:3893-3904. (Pubitemid 37279305)
29. Iba K, Albrechtsen R, Gilpin B, et al.: The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to beta1 integrin-dependent cell spreading. J Cell Biol 2000;149:1143-1156. (Pubitemid 30354263)
30. Galliano MF, Huet C, Frygelius J, et al.: Binding of ADAM12, a marker of skeletal muscle regeneration, to the muscle-specific actin-binding protein, alpha-actinin-2, is required for myoblast fusion. J Biol Chem 2000;275:13933-13939. (Pubitemid 30257470)
31. Kang Q, Cao Y, Zolkiewska A: Metalloprotease disintegrin ADAM 12 binds to the SH3 domain of Src and activates Src tyrosine kinase in C2C12 cells. Biochem J 2000;352:883-892. (Pubitemid 32015046)
32. Suzuki A, Kadota N, Hara T, et al.: Meltrin alpha cytoplasmic domain interacts with SH3 domains of Src and Grb2 and is phosphorylated by v-Src. Oncogene 2000;19:5842-5850. (Pubitemid 32005364)
33. Kang Q, Cao Y, Zolkiewska A: Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells. J Biol Chem 2001;276:24466-24472. (Pubitemid 37412907)
34. Seals DF, Azucena EF, Jr., Pass I, et al.: The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells. Cancer Cell 2005;7:155-165. (Pubitemid 40248341)
35. Tanaka M, Nanba D, Mori S, et al.: ADAM binding protein Eve-1 is required for ectodomain shedding of epidermal growth factor receptor ligands. J Biol Chem 2004;279:41950-41959. (Pubitemid 39313645)
36. Mori S, Tanaka M, Nanba D, et al.: PACSIN3 binds ADAM12/meltrin alpha and up-regulates ectodomain shedding of heparin-binding epidermal growth factor-like growth factor. J Biol Chem 2003;278:46029-46034. (Pubitemid 37432752)
37. Cao Y, Kang Q, Zhao Z, et al.: Intracellular processing of metalloprotease disintegrin ADAM12. J Biol Chem 2002;277:26403-26411. (Pubitemid 34967134)
38. Sundberg C, Thodeti CK, Kveiborg M, et al.: Regulation of ADAM12 cell surface expression by protein kinase C epsilon. J Biol Chem 2004;279:51601- 51611. (Pubitemid 40017911)
39. Peduto L, Reuter VE, Sehara-Fujisawa A, et al.: ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression. Oncogene 2006;25:5462-5466. (Pubitemid 44330288)
40. Roy R, Wewer UM, Zurakowski D, et al.: ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 2004;279:51323-51330. (Pubitemid 40017878)